Advertisement
Singapore markets closed

  • Straits Times Index

    3,297.55
    -26.98 (-0.81%)
     

  • Nikkei

    38,814.56
    +94.09 (+0.24%)
     

  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • Bitcoin USD

    66,090.41
    -9.37 (-0.01%)
     

  • CMC Crypto 200

    1,404.32
    -13.56 (-0.96%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • Dow

    38,589.16
    -57.94 (-0.15%)
     

  • Nasdaq

    17,688.88
    +21.32 (+0.12%)
     

  • Gold

    2,348.40
    +30.40 (+1.31%)
     

  • Crude Oil

    78.49
    -0.13 (-0.17%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • FTSE Bursa Malaysia

    1,607.32
    -2.85 (-0.18%)
     

  • Jakarta Composite Index

    6,734.83
    -96.73 (-1.42%)
     

  • PSE Index

    6,383.70
    -7.13 (-0.11%)
     

Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns

Vandana Singh
·2-min read
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns

Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns.

Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide.

Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks.

Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users.

Demand for Ozempic and Mounjaro has surged due to their effectiveness in weight loss. However, the popularity of these medications has led to shortages, prompting some patients to turn to compounded alternatives.

ADVERTISEMENT

Compounded drugs are custom-made versions based on the same ingredients as branded drugs. While often cheaper, they lack clinical evaluation by regulators for safety, quality, or efficacy. Butler noted a rise in reports of adverse events linked to these GLP-1 copies, including a serious incident that resulted in hospitalization.

Reuters noted that to protect public health, Butler announced new regulations to remove GLP-1 receptor agonists, such as those being misrepresented and sold as replicas of Ozempic or Mounjaro, from pharmacy compounding exemptions starting October 1.

This timeframe allows patients to transition to regulated drugs. Currently, around 20,000 Australians use pharmacy-made compounded versions of Ozempic and Mounjaro, primarily for weight loss, Reuters noted.

In February, FDA Commissioner Dr. Robert Califf expressed concerns about the online prevalence of compounded weight-loss drugs.

In April, U.S. District Judge Roy Altman ruled that Eli Lilly cannot rely on state law to stop a compounding pharmacy, RXCompoundStore.com, from marketing its version of the drug tirzepatide.

Price Action: NVO shares are down 0.76% at $134.14, and LLY stock is down 0.60% at $798.32 at last check Wednesday.

Image Via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.